Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Myeloid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm

Cancer Family

Myeloid Neoplasm

CI-CAN-00000279Explore in graph →

HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items

NCIt: C9290
OncoTree: MNM
DOID: 0070004

Overview
Statistics
Survival
Genomics22
Variants & evidence653
Drugs61
Trials4789
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (234)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 234 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.
· Leukemia · 2006 · PMID 16307017 · validated civic_curation pubmed
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
· J Clin Oncol · 2012 · PMID 22753902 · validated civic_curation pubmed
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
· Leuk Res · 2014 · PMID 24836762 · validated civic_curation pubmed
Clinical significance of TP53 mutation in myeloma.
· Leukemia · 2007 · PMID 17215851 · validated civic_curation pubmed
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
· Br J Haematol · 2016 · PMID 26771088 · validated civic_curation pubmed
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.
· Am J Hematol · 2012 · PMID 22180162 · validated civic_curation pubmed
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
· Nature · 2012 · PMID 22504184 · validated civic_curation

Showing 51–75 of 234 publications

← Previous
1
2
3
4
…
10
Next →

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

· Blood · 2012 · PMID 22368270 · validated civic_curation pubmed

Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.

· Int J Hematol · 2013 · PMID 23670176 · validated civic_curation pubmed

Assessment of Minimal Residual Disease in Standard-Risk AML.

· N Engl J Med · 2016 · PMID 26789727 · validated civic_curation pubmed

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

· Ann Hematol · 2014 · PMID 24981688 · validated civic_curation pubmed

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.

· Blood Cancer J · 2016 · PMID 27058230 · validated civic_curation pubmed

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

· Nat Med · 2012 · PMID 22426421 · validated civic_curation pubmed

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

· Leukemia · 2013 · PMID 23018865 · validated civic_curation pubmed

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

· N Engl J Med · 2012 · PMID 23190221 · validated civic_curation pubmed

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

· Blood · 2004 · PMID 14504092 · validated civic_curation pubmed

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

· Blood · 2015 · PMID 26486786 · validated civic_curation pubmed

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

· Blood · 2016 · PMID 27288520 · validated civic_curation pubmed

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

· Leukemia · 2014 · PMID 24496303 · validated civic_curation pubmed

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

· N Engl J Med · 2016 · PMID 27355533 · validated civic_curation pubmed

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

· Leukemia · 2016 · PMID 26464169 · validated civic_curation pubmed

CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia.

· Leukemia · 2006 · PMID 16307009 · validated civic_curation pubmed

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

· Blood · 2009 · PMID 19779040 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

· Lancet Oncol · 2017 · PMID 28645776 · validated civic_curation pubmed